Bioinformatic analyses showed that the expression level of C‐C motif chemokine ligand 5 (CCL5) was significantly higher in patients with GBM than in healthy subjects; thus, it may be used as a target to guide drug delivery.[137] Zhang et al. Here, CCL5 is linked to glioblastoma.